Carmela Nappi

Implications of COVID-19 Infection on Medication Adherence with Chronic Therapies in Italy: A Proposed Observational Investigation by the Fail-to-Refill Project

Luca Degli Esposti, Stefano Buda, Carmela Nappi et al. · Risk Management and Healthcare Policy · 2020 · 50 citations · Full text

Pharmacy, Clinical Pharmacy, Disease Surveillance +16

Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy

Umberto Restelli, A. Albertí, Adriano Lazzarin et al. · The European Journal of Health Economics · 2016 · 11 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +16

Trial-based cost-effectiveness of abatacept for rheumatoid arthritis patients in Italy

J Gaultney, Maurizio Benucci, Sergio Iannazzo et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 2015 · 10 citations

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Budget impact analysis of the simplification to atazanavir + ritonavir + lamivudine dual therapy of HIV-positive patients receiving atazanavir-based triple therapies in Italy starting from data of the Atlas-M trial

Umberto Restelli, Massimiliano Fabbiani, Simona Di Giambenedetto et al. · ClinicoEconomics and Outcomes Research · 2017 · 10 citations · Full text

Pharmacy, Pharmacoeconomics, Pharmacotherapy +17

Cost per response for abatacept versus adalimumab in rheumatoid arthritis by ACPA subgroups in Germany, Italy, Spain, US and Canada

L. Weijers, Christoph Baerwald, Francesco Saverio Mennini et al. · Rheumatology International · 2017 · 10 citations · Full text

Medicine, Internal Medicine, Pharmacotherapy +17